Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers

NCT04471519 is registered in ClinicalTrials.gov with Bharat Biotech International Limited as lead sponsor.

NCT NCT04471519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04471519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers
Lead sponsor
Bharat Biotech International Limited
Phase
Phase 1/2
Overall status
Completed
Start date
July 15, 2020
Completion date
June 30, 2021
Enrollment
755 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection